vs
Side-by-side financial comparison of ARGENX SE (ARGX) and Roper Technologies (ROP). Click either name above to swap in a different company.
ARGENX SE is the larger business by last-quarter revenue ($2.5B vs $2.1B, roughly 1.2× Roper Technologies). ARGENX SE runs the higher net margin — 35.5% vs 15.8%, a 19.7% gap on every dollar of revenue. On growth, ARGENX SE posted the faster year-over-year revenue change (83.2% vs 11.3%). Roper Technologies produced more free cash flow last quarter ($507.0M vs $322.4M).
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. They have produced drugs to treat a wide range of medical issues.
Roper Technologies, Inc. is a holding company that owns companies in the technology sector.
ARGX vs ROP — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $2.5B | $2.1B |
| Net Profit | $877.2M | $331.0M |
| Gross Margin | 89.5% | 69.4% |
| Operating Margin | 28.9% | 27.2% |
| Net Margin | 35.5% | 15.8% |
| Revenue YoY | 83.2% | 11.3% |
| Net Profit YoY | 1.3% | 53.7% |
| EPS (diluted) | $13.25 | $4.87 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $2.1B | ||
| Q4 25 | $2.5B | $2.1B | ||
| Q3 25 | — | $2.0B | ||
| Q2 25 | $1.8B | $1.9B | ||
| Q1 25 | — | $1.9B | ||
| Q4 24 | $1.4B | $1.9B | ||
| Q3 24 | — | $1.8B | ||
| Q2 24 | $901.9M | $1.7B |
| Q1 26 | — | $331.0M | ||
| Q4 25 | $877.2M | $428.4M | ||
| Q3 25 | — | $398.5M | ||
| Q2 25 | $414.8M | $378.3M | ||
| Q1 25 | — | $331.1M | ||
| Q4 24 | $865.6M | $462.3M | ||
| Q3 24 | — | $367.9M | ||
| Q2 24 | $-32.5M | $337.1M |
| Q1 26 | — | 69.4% | ||
| Q4 25 | 89.5% | 69.5% | ||
| Q3 25 | — | 69.5% | ||
| Q2 25 | 89.2% | 69.2% | ||
| Q1 25 | — | 68.7% | ||
| Q4 24 | 90.2% | 68.3% | ||
| Q3 24 | — | 69.2% | ||
| Q2 24 | 89.4% | 69.5% |
| Q1 26 | — | 27.2% | ||
| Q4 25 | 28.9% | 28.6% | ||
| Q3 25 | — | 28.4% | ||
| Q2 25 | 19.2% | 28.2% | ||
| Q1 25 | — | 27.9% | ||
| Q4 24 | 8.7% | 28.0% | ||
| Q3 24 | — | 28.1% | ||
| Q2 24 | -15.4% | 28.8% |
| Q1 26 | — | 15.8% | ||
| Q4 25 | 35.5% | 20.8% | ||
| Q3 25 | — | 19.8% | ||
| Q2 25 | 23.4% | 19.5% | ||
| Q1 25 | — | 17.6% | ||
| Q4 24 | 64.1% | 24.6% | ||
| Q3 24 | — | 20.8% | ||
| Q2 24 | -3.6% | 19.6% |
| Q1 26 | — | $4.87 | ||
| Q4 25 | $13.25 | $3.97 | ||
| Q3 25 | — | $3.68 | ||
| Q2 25 | $6.32 | $3.49 | ||
| Q1 25 | — | $3.06 | ||
| Q4 24 | $13.33 | $4.29 | ||
| Q3 24 | — | $3.40 | ||
| Q2 24 | $-0.55 | $3.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $3.5B | $382.9M |
| Total DebtLower is stronger | — | $9.7B |
| Stockholders' EquityBook value | $7.3B | $18.8B |
| Total Assets | $8.7B | $34.6B |
| Debt / EquityLower = less leverage | — | 0.52× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $382.9M | ||
| Q4 25 | $3.5B | $297.4M | ||
| Q3 25 | — | $320.0M | ||
| Q2 25 | $2.1B | $242.4M | ||
| Q1 25 | — | $372.8M | ||
| Q4 24 | $1.5B | $188.2M | ||
| Q3 24 | — | $269.6M | ||
| Q2 24 | $1.4B | $251.5M |
| Q1 26 | — | $9.7B | ||
| Q4 25 | — | $9.3B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | — | — | ||
| Q2 24 | $11.0M | — |
| Q1 26 | — | $18.8B | ||
| Q4 25 | $7.3B | $19.9B | ||
| Q3 25 | — | $20.0B | ||
| Q2 25 | $6.1B | $19.6B | ||
| Q1 25 | — | $19.2B | ||
| Q4 24 | $5.5B | $18.9B | ||
| Q3 24 | — | $18.5B | ||
| Q2 24 | $4.3B | $18.1B |
| Q1 26 | — | $34.6B | ||
| Q4 25 | $8.7B | $34.6B | ||
| Q3 25 | — | $34.6B | ||
| Q2 25 | $7.2B | $33.2B | ||
| Q1 25 | — | $31.4B | ||
| Q4 24 | $6.2B | $31.3B | ||
| Q3 24 | — | $31.6B | ||
| Q2 24 | $4.8B | $29.8B |
| Q1 26 | — | 0.52× | ||
| Q4 25 | — | 0.47× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.40× | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.00× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $323.3M | — |
| Free Cash FlowOCF − Capex | $322.4M | $507.0M |
| FCF MarginFCF / Revenue | 13.0% | 24.2% |
| Capex IntensityCapex / Revenue | 0.0% | 0.5% |
| Cash ConversionOCF / Net Profit | 0.37× | — |
| TTM Free Cash FlowTrailing 4 quarters | $594.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $323.3M | $738.0M | ||
| Q3 25 | — | $869.5M | ||
| Q2 25 | $361.8M | $404.1M | ||
| Q1 25 | — | $528.7M | ||
| Q4 24 | $41.9M | $722.2M | ||
| Q3 24 | — | $755.4M | ||
| Q2 24 | $-124.7M | $384.1M |
| Q1 26 | — | $507.0M | ||
| Q4 25 | $322.4M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $356.6M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $40.9M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-125.5M | — |
| Q1 26 | — | 24.2% | ||
| Q4 25 | 13.0% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 20.1% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 3.0% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -13.9% | — |
| Q1 26 | — | 0.5% | ||
| Q4 25 | 0.0% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.3% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.1% | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.37× | 1.72× | ||
| Q3 25 | — | 2.18× | ||
| Q2 25 | 0.87× | 1.07× | ||
| Q1 25 | — | 1.60× | ||
| Q4 24 | 0.05× | 1.56× | ||
| Q3 24 | — | 2.05× | ||
| Q2 24 | — | 1.14× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
